Iovance Biotherapeutics, Inc. Q2 2025 Earnings Recap

IOVA Q2 2025 August 8, 2025

Get alerts when IOVA reports next quarter

Iovance Biotherapeutics reported strong Q2 2025 performance with revenue of $60 million, driven by the successful rollout of Amtagvi, and announced a strategic restructuring to improve margins and operational efficiency.

Earnings Per Share Miss

$-0.33 vs $-0.29 est.

-13.8% surprise

Revenue Miss

59952000 vs 78321430 est.

-23.5% surprise

Market Reaction

1-Day -6.64%

5-Day +20.85%

30-Day +12.8%

See IOVA alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue grew 22% sequentially to $60 million, with Amtagvi infusions contributing $54 million.
The company reaffirms 2025 revenue guidance of $250 million to $300 million, underpinned by strong demand for Amtagvi.
A strategic restructuring, including a 19% workforce reduction, is projected to yield over $100 million in annual cost savings starting Q4 2025.
Gross margin stood at 31%, with expectations for improvement through reduced costs of sales and enhanced manufacturing capacity utilization.
Strong real-world data indicates a nearly 49% response rate for Amtagvi, with plans to onboard large community practices in Q4 2025.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit IOVA on AllInvestView.

Next Q3 2025